Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
Conditions
- B-Cell Non-Hodgkin Lymphoma
- Burkitt Lymphoma
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
- High Grade B-Cell Lymphoma, Not Otherwise Specified
- Primary Mediastinal Large B-Cell Lymphoma
- T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
- Transformed B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma to Diffuse Large B-Ce
Interventions
- PROCEDURE: Biospecimen Collection
- PROCEDURE: Bone Marrow Aspiration
- PROCEDURE: Bone Marrow Biopsy
- PROCEDURE: Computed Tomography
- DRUG: Cyclophosphamide
- DRUG: Doxorubicin
- PROCEDURE: Echocardiography Test
- BIOLOGICAL: Epcoritamab
- DRUG: Etoposide
- OTHER: Fludeoxyglucose F-18
- PROCEDURE: Multigated Acquisition Scan
- PROCEDURE: Positron Emission Tomography
- DRUG: Prednisone
- BIOLOGICAL: Rituximab
Sponsor
University of Washington
Collaborators